- Current report filing (8-K)
February 28 2011 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): February 28, 2011
Idenix Pharmaceuticals,
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49839
|
|
45-0478605
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
60 Hampshire
Street
Cambridge, MA
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
617-995-9800
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 2.02. Results of
Operations and Financial Condition
On February 28,
2011, Idenix Pharmaceuticals, Inc. announced its financial results for the
quarter and year ended December 31, 2010. The full text of the press
release issued in connection with the announcement is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in
this Form 8-K (including Exhibit 99.1) shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements
and Exhibits
(d) Exhibits
The following exhibit
relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release
dated February 28, 2011.
2
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc.
|
|
Date: February 28, 2011
|
By:
|
/s/ Maria Stahl
|
|
|
|
Maria Stahl
|
|
|
|
Senior Vice President and
General Counsel
|
|
|
3
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press release dated February 28, 2011
|
4
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Aug 2023 to Aug 2024